Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

Global HIV Treatment - Turning Headwinds to Tailwinds.

Havlir DV, Doherty MC.

N Engl J Med. 2019 Aug 29;381(9):873-874. doi: 10.1056/NEJMe1909363. Epub 2019 Jul 24. No abstract available.

PMID:
31339675
2.

Safety study of live, oral human rotavirus vaccine: A cohort study in United States health insurance plans.

Hoffman V, Abu-Elyazeed R, Enger C, Esposito DB, Doherty MC, Quinlan SC, Skerry K, Holick CN, Basile P, Friedland LR, Praet N, Wéry S, Willame C, Dore DD, Rosillon D.

Hum Vaccin Immunother. 2018 Jul 3;14(7):1782-1790. doi: 10.1080/21645515.2018.1450123. Epub 2018 Apr 13.

3.

Sharing post-AML consolidation supportive therapy with local centers reduces patient travel burden without compromising outcomes.

Hershenfeld SA, Maki K, Rothfels L, Murray CS, Nixon S, Schimmer AD, Doherty MC.

Leuk Res. 2017 Aug;59:93-96. doi: 10.1016/j.leukres.2017.05.023. Epub 2017 Jun 1.

PMID:
28599190
4.

Hypoglycaemia seriousness and weight gain as determinants of cardiovascular disease outcomes among sulfonylurea users.

Nunes AP, Iglay K, Radican L, Engel SS, Yang J, Doherty MC, Dore DD.

Diabetes Obes Metab. 2017 Oct;19(10):1425-1435. doi: 10.1111/dom.13000. Epub 2017 Jul 21.

PMID:
28497592
5.

Safety of Tenofovir Disoproxil Fumarate-Based Antiretroviral Therapy Regimens in Pregnancy for HIV-Infected Women and Their Infants: A Systematic Review and Meta-Analysis.

Nachega JB, Uthman OA, Mofenson LM, Anderson JR, Kanters S, Renaud F, Ford N, Essajee S, Doherty MC, Mills EJ.

J Acquir Immune Defic Syndr. 2017 Sep 1;76(1):1-12. doi: 10.1097/QAI.0000000000001359. Review.

6.

Performance-based financing for improving HIV/AIDS service delivery: a systematic review.

Suthar AB, Nagata JM, Nsanzimana S, Bärnighausen T, Negussie EK, Doherty MC.

BMC Health Serv Res. 2017 Jan 4;17(1):6. doi: 10.1186/s12913-016-1962-9. Review.

7.

Timing of initiation of antiretroviral therapy and adverse pregnancy outcomes: a systematic review and meta-analysis.

Uthman OA, Nachega JB, Anderson J, Kanters S, Mills EJ, Renaud F, Essajee S, Doherty MC, Mofenson LM.

Lancet HIV. 2017 Jan;4(1):e21-e30. doi: 10.1016/S2352-3018(16)30195-3. Epub 2016 Nov 16. Review.

8.

Assessing occurrence of hypoglycemia and its severity from electronic health records of patients with type 2 diabetes mellitus.

Nunes AP, Yang J, Radican L, Engel SS, Kurtyka K, Tunceli K, Yu S, Iglay K, Doherty MC, Dore DD.

Diabetes Res Clin Pract. 2016 Nov;121:192-203. doi: 10.1016/j.diabres.2016.09.012. Epub 2016 Sep 21.

PMID:
27744128
9.
10.

Co-trimoxazole prophylaxis in adults, including pregnant women, with HIV: a systematic review and meta-analysis.

Suthar AB, Vitoria MA, Nagata JM, Anglaret X, Mbori-Ngacha D, Sued O, Kaplan JE, Doherty MC.

Lancet HIV. 2015 Apr;2(4):e137-50. doi: 10.1016/S2352-3018(15)00005-3. Epub 2015 Mar 3. Review.

PMID:
26424674
11.

Co-trimoxazole in people on antiretroviral therapy for HIV--authors' reply.

Suthar AB, Vitoria MA, Doherty MC.

Lancet HIV. 2015 Jun;2(6):e227-8. doi: 10.1016/S2352-3018(15)00085-5. Epub 2015 May 27. No abstract available.

PMID:
26423193
12.

Definitions of implementation science in HIV/AIDS.

Odeny TA, Padian N, Doherty MC, Baral S, Beyrer C, Ford N, Geng EH.

Lancet HIV. 2015 May;2(5):e178-80. doi: 10.1016/S2352-3018(15)00061-2. Epub 2015 Apr 28. No abstract available.

PMID:
26423000
13.

Developing the 2013 WHO consolidated antiretroviral guidelines.

Easterbrook PJ, Irvine CJ, Vitoria M, Shaffer N, Muhe LM, Negussie EK, Doherty MC, Ball A, Hirnschall G.

AIDS. 2014 Mar;28 Suppl 2:S93-100. doi: 10.1097/QAD.0000000000000253. No abstract available.

PMID:
24849484
14.

Health systems implications of the 2013 WHO consolidated antiretroviral guidelines and strategies for successful implementation.

Holmes C, Pillay Y, Mwango A, Perriens J, Ball A, Barreneche O, Wignall S, Hirnschall G, Doherty MC.

AIDS. 2014 Mar;28 Suppl 2:S231-9. doi: 10.1097/QAD.0000000000000250. No abstract available.

PMID:
24849483
15.

The impact and cost of the 2013 WHO recommendations on eligibility for antiretroviral therapy.

Stover J, Gopalappa C, Mahy M, Doherty MC, Easterbrook PJ, Weiler G, Ghys PD.

AIDS. 2014 Mar;28 Suppl 2:S225-30. doi: 10.1097/QAD.0000000000000235.

PMID:
24849482
16.

Adoption of national recommendations related to use of antiretroviral therapy before and shortly following the launch of the 2013 WHO consolidated guidelines.

Nelson LJ, Beusenberg M, Habiyambere V, Shaffer N, Vitoria MA, Montero RG, Easterbrook PJ, Doherty MC.

AIDS. 2014 Mar;28 Suppl 2:S217-24. doi: 10.1097/QAD.0000000000000239.

PMID:
24849481
17.

Improving antiretroviral therapy scale-up and effectiveness through service integration and decentralization.

Suthar AB, Rutherford GW, Horvath T, Doherty MC, Negussie EK.

AIDS. 2014 Mar;28 Suppl 2:S175-85. doi: 10.1097/QAD.0000000000000259.

PMID:
24849478
18.

Predicting treatment failure in adults and children on antiretroviral therapy: a systematic review of the performance characteristics of the 2010 WHO immunologic and clinical criteria for virologic failure.

Rutherford GW, Anglemyer A, Easterbrook PJ, Horvath T, Vitoria M, Penazzato M, Doherty MC.

AIDS. 2014 Mar;28 Suppl 2:S161-9. doi: 10.1097/QAD.0000000000000236. Review.

PMID:
24849476
19.

Optimal strategies for monitoring response to antiretroviral therapy in HIV-infected adults, adolescents, children and pregnant women: a systematic review.

Tucker JD, Bien CH, Easterbrook PJ, Doherty MC, Penazzato M, Vitoria M, Peeling RW.

AIDS. 2014 Mar;28 Suppl 2:S151-60. doi: 110.1097/QAD.0000000000000230. Review.

PMID:
24849475
20.

Early initiation of antiretroviral therapy in HIV-infected adults and adolescents: a systematic review.

Anglemyer A, Rutherford GW, Easterbrook PJ, Horvath T, Vitória M, Jan M, Doherty MC.

AIDS. 2014 Mar;28 Suppl 2:S105-18. doi: 10.1097/QAD.0000000000000232. Review.

PMID:
24849469
21.

The role of mathematical modelling in the development of recommendations in the 2013 WHO consolidated antiretroviral therapy guidelines.

Easterbrook PJ, Doherty MC, Perriëns JH, Barcarolo JL, Hirnschall GO.

AIDS. 2014 Jan;28 Suppl 1:S85-92. doi: 10.1097/QAD.0000000000000111.

PMID:
24468950
22.

The next generation of the World Health Organization's global antiretroviral guidance.

Hirnschall G, Harries AD, Easterbrook PJ, Doherty MC, Ball A.

J Int AIDS Soc. 2013 Jun 30;16:18757. doi: 10.7448/IAS.16.1.18757.

23.

Postmarketing evaluation of the short-term safety of the pentavalent rotavirus vaccine.

Loughlin J, Mast TC, Doherty MC, Wang FT, Wong J, Seeger JD.

Pediatr Infect Dis J. 2012 Mar;31(3):292-6. doi: 10.1097/INF.0b013e3182421390.

PMID:
22173146
24.

The prevalence and risk factors associated with esophageal varices in subjects with hepatitis C and advanced fibrosis.

Sanyal AJ, Fontana RJ, Di Bisceglie AM, Everhart JE, Doherty MC, Everson GT, Donovan JA, Malet PF, Mehta S, Sheikh MY, Reid AE, Ghany MG, Gretch DR, Halt-C Trial Group.

Gastrointest Endosc. 2006 Dec;64(6):855-64.

PMID:
17140886
25.

Improved adherence and less toxicity with rifampin vs isoniazid for treatment of latent tuberculosis: a retrospective study.

Page KR, Sifakis F, Montes de Oca R, Cronin WA, Doherty MC, Federline L, Bur S, Walsh T, Karney W, Milman J, Baruch N, Adelakun A, Dorman SE.

Arch Intern Med. 2006 Sep 25;166(17):1863-70.

PMID:
17000943
26.

Severe community-acquired pneumonia due to Staphylococcus aureus, 2003-04 influenza season.

Hageman JC, Uyeki TM, Francis JS, Jernigan DB, Wheeler JG, Bridges CB, Barenkamp SJ, Sievert DM, Srinivasan A, Doherty MC, McDougal LK, Killgore GE, Lopatin UA, Coffman R, MacDonald JK, McAllister SK, Fosheim GE, Patel JB, McDonald LC.

Emerg Infect Dis. 2006 Jun;12(6):894-9.

27.

Portal hypertensive gastropathy in chronic hepatitis C patients with bridging fibrosis and compensated cirrhosis: results from the HALT-C trial.

Fontana RJ, Sanyal AJ, Mehta S, Doherty MC, Neuschwander-Tetri BA, Everson GT, Kahn JA, Malet PF, Sheikh MY, Chung RT, Ghany MG, Gretch DR; HALT-C Trial Group.

Am J Gastroenterol. 2006 May;101(5):983-92.

28.

Hepatitis C virus-specific immune responses and quasi-species variability at baseline are associated with nonresponse to antiviral therapy during advanced hepatitis C.

Morishima C, Polyak SJ, Ray R, Doherty MC, Di Bisceglie AM, Malet PF, Bonkovsky HL, Sullivan DG, Gretch DR, Rothman AL, Koziel MJ, Lindsay KL; Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis Trial Group.

J Infect Dis. 2006 Apr 1;193(7):931-40. Epub 2006 Feb 22.

PMID:
16518754
29.

Viral latency and reservoirs: relevance for mother-to-child transmission and resistance.

Wind-Rotolo M, Doherty MC.

Curr Opin HIV AIDS. 2006 Mar;1(2):167-73. doi: 10.1097/01.COH.0000203832.16597.aa.

PMID:
19372803
30.

Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes.

Francis JS, Doherty MC, Lopatin U, Johnston CP, Sinha G, Ross T, Cai M, Hansel NN, Perl T, Ticehurst JR, Carroll K, Thomas DL, Nuermberger E, Bartlett JG.

Clin Infect Dis. 2005 Jan 1;40(1):100-7. Epub 2004 Dec 7.

PMID:
15614698
31.

Solid-pseudopapillary tumor of the pancreas.

Coleman KM, Doherty MC, Bigler SA.

Radiographics. 2003 Nov-Dec;23(6):1644-8. No abstract available.

PMID:
14615569
32.

Implementation of the STOP protocol for Stroke Prevention in Sickle Cell Anemia by using duplex power Doppler imaging.

Malouf AJ Jr, Hamrick-Turner JE, Doherty MC, Dhillon GS, Iyer RV, Smith MG.

Radiology. 2001 May;219(2):359-65.

PMID:
11323457
33.

How cigarette additives are used to mask environmental tobacco smoke.

Connolly GN, Wayne GD, Lymperis D, Doherty MC.

Tob Control. 2000 Sep;9(3):283-91.

34.

Gender differences in the initiation of injection drug use among young adults.

Doherty MC, Garfein RS, Monterroso E, Latkin C, Vlahov D.

J Urban Health. 2000 Sep;77(3):396-414.

35.

The effect of a needle exchange program on numbers of discarded needles: a 2-year follow-up.

Doherty MC, Junge B, Rathouz P, Garfein RS, Riley E, Vlahov D.

Am J Public Health. 2000 Jun;90(6):936-9.

36.

Correlates of HIV infection among young adult short-term injection drug users.

Doherty MC, Garfein RS, Monterroso E, Brown D, Vlahov D.

AIDS. 2000 Apr 14;14(6):717-26.

PMID:
10807195
37.

HIV prevalence and risk behaviors among new initiates into injection drug use over the age of 40 years old.

Carneiro M, Fuller C, Doherty MC, Vlahov D.

Drug Alcohol Depend. 1999 Mar 1;54(1):83-6.

PMID:
10101620
38.

Prevalence and incidence of hepatitis C virus infection among young adult injection drug users.

Garfein RS, Doherty MC, Monterroso ER, Thomas DL, Nelson KE, Vlahov D.

J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18 Suppl 1:S11-9.

PMID:
9663618
39.

Gender differences in injection-related behaviors among injection drug users in Baltimore, Maryland.

Latkin CA, Mandell W, Knowlton AR, Doherty MC, Vlahov D, Suh T, Celentano DD.

AIDS Educ Prev. 1998 Jun;10(3):257-63.

PMID:
9642423
40.

Discarded needles do not increase soon after the opening of a needle exchange program.

Doherty MC, Garfein RS, Vlahov D, Junge B, Rathouz PJ, Galai N, Anthony JC, Beilenson P.

Am J Epidemiol. 1997 Apr 15;145(8):730-7.

PMID:
9125999
41.
42.

Acquisition and use of needles and syringes by injecting drug users in Baltimore, Maryland.

Gleghorn AA, Jones TS, Doherty MC, Celentano DD, Vlahov D.

J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Sep 1;10(1):97-103.

PMID:
7648292
43.

Inadequate bleach contact times during syringe cleaning among injection drug users.

Gleghorn AA, Doherty MC, Vlahov D, Celentano DD, Jones TS.

J Acquir Immune Defic Syndr. 1994 Jul;7(7):767-72.

PMID:
8207661
44.

Ferroxidase II activity and serum cholesterol.

Macfarlane SK, Doherty MC, Dormandy TL.

Free Radic Res Commun. 1987;3(1-5):79-83.

PMID:
3508445
45.

Research methodology series. Computerized bibliographic databases.

Doherty MC, Birrer R.

Fam Pract Res J. 1986 Winter;6(2):59-66. No abstract available.

PMID:
3331874

Supplemental Content

Loading ...
Support Center